Drug Trial Radar · NCT07816328
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
382
Planned (sponsor's estimate)
Start
Sep 21, 2026
Primary completion
May 24, 2028
Study completion May 24, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this open-label study is to assess the efficacy and safety of a novel treatment algorithm for sequencing remibrutinib and omalizumab in the treatment of adult participants with chronic spontaneous urticaria (CSU) who are inadequately controlled by second-generation H1-antihistamines (sgH1-AH).
Conditions
- Chronic Spontaneous Urticaria
Interventions
RemibrutinibDrug
Remibrutinib 25 mg twice a day.
OmalizumabDrug
Omalizumab 300 mg every 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving Urticaria Activity Score over 7 days (UAS7) ≤6 (yes/no)Time frame: Week 24
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
London, Ontario, Canada · Recruiting
Novartis Investigative Site
Québec, Quebec, Canada · Recruiting
Novartis Investigative Site
Hong Kong, Hong Kong, Hong Kong · Recruiting
Novartis Investigative Site
Yokohama, Kanagawa, Japan · Recruiting
Novartis Investigative Site
Yokohama, Kanagawa, Japan · Recruiting
Novartis Investigative Site
Kamimashiki-gun, Kumamoto, Japan · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Hwaseong-si, Gyeonggi-do, South Korea · Recruiting
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea · Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.